We use cookies to improve your experience on this website.

News & Events

DPS and TRIA selected to design 200,000 SF GMP mRNA Clinical Manufacturing Facility for Moderna Therapeutics

Wednesday 05 October 2016

DPS, the global engineering group and its US architectural partner TRIA has won a major contract to provide architectural, engineering and project management services for a new $110 million, 200,000-square foot GMP mRNA clinical manufacturing facility in Norwood, Massachusetts, for biotechnology company, Moderna Therapeutics.

DPS is providing full architectural and engineering design for the Norwood facility and also providing construction management oversight, commissioning, qualification and validation and procurement services.  TRIA is designing clinical labs, offices, employee facilities and a conference center. Construction of the new facility is due to begin in October 2016 and be completed in early 2018.

DPS CEO Frank Keogh said, “This is a significant contract win for DPS and builds on the strong relationship we have developed with Moderna. We are proud to be supporting Moderna with this major investment in Norwood. This project demonstrates DPS’s ability to bid for and win large-scale capital investment design projects in the US.”

Moderna Therapeutics is a clinical stage biotechnology company pioneering messenger RNA (mRNA) TherapeuticsTM to create a new generation of transformative medicines for patients. The company’s Norwood facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices (GLP) toxicology studies as well as Phase 1 and Phase 2 clinical studies. Moderna will carry out all manufacturing activities at the site—from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish.

Back to top
DPS Group addresses the COVID-19 pandemic:
A message from Frank Keogh, CEO

Find out more Contact Us